Noteworthy TriGenix done in by a string of bad luck

TriGenix Inc. is planning on closing its doors, a victim both of D. Blech's financial problems and the failure of Celtrix Pharmaceuticals Inc.'s Phase III BetaKine trial to show efficacy in macular holes.

TriGenix was launched in November 1993 to provide a package of services including sales, marketing and reimbursement management, as a third alternative to the choice between companies performing those functions themselves and licensing away products.